NovartisNVS

Novartis is the pharmaceutical group whose January 2024 deal with Isomorphic Labs pays $37.5 million upfront against up to $1.2 billion in milestones, and which added up to three more programs a year later. It holds one of the two milestone schedules the market is watching as the test of Isomorphic's AI drug design engine.